How do you decide among AI, full dose tamoxifen and low dose tamoxifen in a postmenopausal woman with DCIS without contraindications to either therapy?  

My decision about AI vs tamoxifen is based on comparing the risk/benefit ratio for the specific patient. The cause of mortality in post-menopausal women is primarily cardiovascular disease, with osteoporosis also causing significant morbidity and mortality. Degenerative joint disease adversely affec...